RE:RE:RE:RE:RE:RE:RE:MTD and the FDA I have no answer for you, but I wonder if there's a clue in the colorectal study that showed despite taxel not even working as normal chemo on the tumor, it worked when delivered via TH1902. I know lack of efficacy is not resistance. I'm actually ignorant on what causes resistance to a particular chemo.
AMoschitto wrote: On this point, with patients who may have developed resistance to taxol based on their previous treatment history... would bypassing the MDR pump still be effective in the way they talked about in the June presentation? I went to look back at that slide but they have
taken it out of the current presentation.
Curious if people here have thoughts about that as a potential disadvantage of this population (of course acknowledging more sortilin expression in late-stage cancers as making these patients ideal for TH1902 as well).